About Us

Advancing Scar Care Since 1996

Avocet Polymer Technologies, Inc. is a Chicago-based pharmaceutical company dedicated to developing safe and effective therapies for inflamed, painful, and hypertrophic scars. Founded in 1996, Avocet has built a strong reputation for innovation in drug delivery and scar management. The company designs, manufactures, and markets advanced drugs, ointments, and medical devices rooted in proven pharmacology and biopolymer technology to support healing and improve patient outcomes.

Our Leading Scar Care Solutions: Avogel & Avosil

Avocet Polymer Technologies sets itself apart through the rational design and scientific development of therapies for scar treatment and prevention. The company’s two flagship products, Avogel and Avosil, are used by patients around the world for managing healing, burn, and trauma-related scars during the first year after injury. Avocet is dedicated to expanding access to these safe, effective, and affordable therapies in hospitals, pharmacies, and homes across the nation.

Patents & Innovation

Avocet holds over 30 patents and continues to develop innovative products aimed at scar prevention and reduction. Its advanced biopolymer and drug delivery technologies are designed to help minimize scarring of both the skin and internal tissues, supporting improved healing and long-term recovery outcomes.

Avogel-SA Hydrogel Sheeting

Avocet has incorporated the powerful anti-inflammatory and preservative agent salicylic acid in a new hydrogel composition. The new proprietary hydrogel formulation is FDA approved. It is the most adhesive hydrogel on the market and it retains water better than any other hydrogel we have tested. It is thinner, more flexible and more adhesive than the previous hydrogel we have marketed as Avogel. It also contains salicylic acid. This concept is covered in patents filed by Avocet. Avogel-SA® should be more effective than any existing product in controlling scar itching and scar formation, especially when applied in the first year following wound generation. Avogel-SA® should lead to significantly improved functional and cosmetic results for post-surgical patients and survivors of major burns or trauma.

Avosil - V

The second product line that Avocet plans to develop targets older, mature scars. Avocet will develop hydrogels and ointments containing calcium channel blockers to activate scar degradation enzymes, which soften and reduce the size of the scar. This therapeutic approach is also covered by Avocet’s patents. An application for an international patent under the Paris Convention Treaty has been filed.

Avosil - D

Vitamin D3 inhibits NF-kB activation of cell inflammatory responses. Avocet has recently developed a novel formulation of Vitamin D3 to soften and diminish the appearance of older scars. An application for an international patent under the Paris Convention Treaty has been filed